Zoetis Inc. $ZTS Shares Acquired by Lido Advisors LLC

Lido Advisors LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 33.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,889 shares of the company’s stock after buying an additional 9,444 shares during the quarter. Lido Advisors LLC’s holdings in Zoetis were worth $5,909,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Norges Bank purchased a new stake in Zoetis in the second quarter valued at $809,491,000. Nuveen LLC acquired a new position in shares of Zoetis in the 1st quarter valued at about $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after buying an additional 1,995,491 shares during the last quarter. Polen Capital Management LLC grew its holdings in Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Finally, Impax Asset Management Group plc raised its position in Zoetis by 362.6% during the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.7%

Shares of ZTS opened at $127.31 on Tuesday. The stock has a 50 day moving average price of $135.42 and a 200 day moving average price of $148.74. Zoetis Inc. has a one year low of $115.25 and a one year high of $181.85. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The stock has a market capitalization of $56.11 billion, a price-to-earnings ratio of 21.91, a PEG ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the firm posted $1.58 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is presently 33.67%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley dropped their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. KeyCorp initiated coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, BTIG Research reduced their target price on Zoetis from $200.00 to $160.00 and set a “buy” rating for the company in a research note on Wednesday, November 12th. Six investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.